-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In vitro diagnosis, or IVD, refers to products and services that obtain clinical diagnostic information by testing human samples (blood, body fluids, tissues, etc.
) outside the human body to determine diseases or body functions
.
In recent years, with the upgrading of consumption and the entry of capital, the scale of the domestic IVD market has continued to expand
.
Data show that China's IVD market in 2019 was 71.
3 billion yuan
.
It is estimated that by 2030, this market will grow to 288.
15 billion yuan, and its share in the global market will increase to 33.
2%
.
The industry believes that companies with strong product competitiveness in the future are expected to accelerate the increase in volume under the trend of domestic substitution
.
In order to open up the market in the IVD field, cooperation has become a means for many pharmaceutical companies to enhance their competitiveness
.
On the evening of November 23, China Heavy Pharmaceutical Holdings announced that, recently, the company's important subsidiary, China Heavy Pharmaceutical Co.
, Ltd.
, and Zhongyuan Huiji signed the "Strategic Cooperation Framework Agreement".
The two parties will give full play to their respective advantages in the development and maintenance of the IVD market.
Carry out in-depth cooperation
.
Public information shows that Zhongyuan Huiji is an enterprise specializing in the research and development, production, sales and technical services of in vitro diagnostic reagents and instruments.
Its main business covers biochemical, immunological, molecular, POCT, clinical examination, microbiological and pathological diagnosis.
Products and upstream raw materials, with genetic engineering antigens/antibodies, diagnostic nanomaterials, high-precision diagnostic equipment and core component development, multiple label signal amplification, rapid nucleic acid extraction and detection and other core technologies
.
Zhongyuan Huiji has strong R&D capabilities.
Currently, there are more than 3,200 employees worldwide, of which R&D and technical service personnel account for nearly half of the total number.
The company plans to invest in R&D each year as a proportion of sales revenue not less than 15%
.
The current annual production capacity can reach 2 billion reagent servings and 20,000 instruments
.
Heavy Pharmaceutical Holdings is mainly engaged in pharmaceutical retail and wholesale business.
The company is a modern large-scale pharmaceutical circulation enterprise serving the entire pharmaceutical industry chain
.
The cooperation between Zhongyuan Huiji has a strong strength in the field of in vitro diagnostics, and the cooperation between the two parties is expected to form complementary resources and accelerate the development of the in vitro diagnostic industry.
.
The announcement shows that China Heavy Pharmaceutical Co.
, Ltd.
and Zhongyuan Huiji have a history of cooperation.
China Heavy Pharmaceutical Holdings has been selling Zhongyuan Huiji's IVD products since 2019.
In 2019 and 2020, the company's sales of Zhongyuan Huiji IVD products accounted for The company's medical device business revenue accounted for 0.
01% and 1.
07%, respectively
.
The content of this agreement shows that Zhongyuan Huiji timely provides the regional IVD market information to Zhongyuan Huiji, and the subsidiaries of Zhongyuan Huiji provide necessary product distribution flow and terminal information to Zhongyuan Huiji to assist Zhongyuan Huiji in the development and Maintain end markets at all levels
.
At the same time, it will further deepen cooperation in government procurement, including the storage of anti-epidemic materials such as nucleic acid extraction reagents, nucleic acid extractors, nucleic acid detection reagents, and virus sampling tubes
.
In addition, in order to continue to make good use of the favorable opportunities of the new medical reform policy to support the development of primary medical care, Zhongyuan Huiji will continue to unite with the subsidiaries of Heavy Pharmaceuticals in various regions to jointly promote and carry out the strategic cooperation between the two parties in the development of primary medical market
.
Regarding this cooperation, Heavy Pharmaceutical Holdings stated that the signing of this agreement is in line with the national industrial policy and the company's mid- and long-term strategic planning, which is conducive to the formation of cooperation between the company and the industry's advantageous resources, opens the market in the IVD field, and promotes the company's relevant segmentation in the device field.
Field development
.
) outside the human body to determine diseases or body functions
.
In recent years, with the upgrading of consumption and the entry of capital, the scale of the domestic IVD market has continued to expand
.
Data show that China's IVD market in 2019 was 71.
3 billion yuan
.
It is estimated that by 2030, this market will grow to 288.
15 billion yuan, and its share in the global market will increase to 33.
2%
.
The industry believes that companies with strong product competitiveness in the future are expected to accelerate the increase in volume under the trend of domestic substitution
.
In order to open up the market in the IVD field, cooperation has become a means for many pharmaceutical companies to enhance their competitiveness
.
On the evening of November 23, China Heavy Pharmaceutical Holdings announced that, recently, the company's important subsidiary, China Heavy Pharmaceutical Co.
, Ltd.
, and Zhongyuan Huiji signed the "Strategic Cooperation Framework Agreement".
The two parties will give full play to their respective advantages in the development and maintenance of the IVD market.
Carry out in-depth cooperation
.
Public information shows that Zhongyuan Huiji is an enterprise specializing in the research and development, production, sales and technical services of in vitro diagnostic reagents and instruments.
Its main business covers biochemical, immunological, molecular, POCT, clinical examination, microbiological and pathological diagnosis.
Products and upstream raw materials, with genetic engineering antigens/antibodies, diagnostic nanomaterials, high-precision diagnostic equipment and core component development, multiple label signal amplification, rapid nucleic acid extraction and detection and other core technologies
.
Zhongyuan Huiji has strong R&D capabilities.
Currently, there are more than 3,200 employees worldwide, of which R&D and technical service personnel account for nearly half of the total number.
The company plans to invest in R&D each year as a proportion of sales revenue not less than 15%
.
The current annual production capacity can reach 2 billion reagent servings and 20,000 instruments
.
Heavy Pharmaceutical Holdings is mainly engaged in pharmaceutical retail and wholesale business.
The company is a modern large-scale pharmaceutical circulation enterprise serving the entire pharmaceutical industry chain
.
The cooperation between Zhongyuan Huiji has a strong strength in the field of in vitro diagnostics, and the cooperation between the two parties is expected to form complementary resources and accelerate the development of the in vitro diagnostic industry.
.
The announcement shows that China Heavy Pharmaceutical Co.
, Ltd.
and Zhongyuan Huiji have a history of cooperation.
China Heavy Pharmaceutical Holdings has been selling Zhongyuan Huiji's IVD products since 2019.
In 2019 and 2020, the company's sales of Zhongyuan Huiji IVD products accounted for The company's medical device business revenue accounted for 0.
01% and 1.
07%, respectively
.
The content of this agreement shows that Zhongyuan Huiji timely provides the regional IVD market information to Zhongyuan Huiji, and the subsidiaries of Zhongyuan Huiji provide necessary product distribution flow and terminal information to Zhongyuan Huiji to assist Zhongyuan Huiji in the development and Maintain end markets at all levels
.
At the same time, it will further deepen cooperation in government procurement, including the storage of anti-epidemic materials such as nucleic acid extraction reagents, nucleic acid extractors, nucleic acid detection reagents, and virus sampling tubes
.
In addition, in order to continue to make good use of the favorable opportunities of the new medical reform policy to support the development of primary medical care, Zhongyuan Huiji will continue to unite with the subsidiaries of Heavy Pharmaceuticals in various regions to jointly promote and carry out the strategic cooperation between the two parties in the development of primary medical market
.
Regarding this cooperation, Heavy Pharmaceutical Holdings stated that the signing of this agreement is in line with the national industrial policy and the company's mid- and long-term strategic planning, which is conducive to the formation of cooperation between the company and the industry's advantageous resources, opens the market in the IVD field, and promotes the company's relevant segmentation in the device field.
Field development
.
